We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · June 30, 2022

Long-Term Safety of Patients With Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood Advances


Additional Info

Blood Advances
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Blood Adv 2022 Jun 10;6(8)14-15, U Jaeger, CS Tam, P Borchmann, JP McGuirk, M Johansen, EK Waller, SM Jaglowski, C Andreadis, RR Foley, JR Westin, I Fleury, PJ Ho, S Mielke, T Teshima, GA Salles, SJ Schuster, FC He, RT Maziarz, SA Mayer, S Makita, MJ Kersten, M Ghosh, ND Wagner-Johnston, K Kato, P Corradini, H Goto, S Colicino, A Agarwal, CL Lobetti-Bodoni, MR Bishop

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading